search button
Open Access

Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content

  • Authors:
    • Daniela Terracciano
    • Claudia Mazzarella
    • Angelina Di Carlo
    • Angela Mariano
    • Matteo Ferro
    • Giuseppe Di Lorenzo
    • Antonio Giordano
    • Vincenzo Altieri
    • Sabino De Placido
    • Vincenzo Macchia

  • View Affiliations

  • Published online on: July 1, 2010     https://doi.org/10.3892/or_00000848
  • Pages: 213-217
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate cancer is one of the most frequently diagnosed cancer in men. Treatment by radical prostatectomy, radiotherapy and anti-androgen drugs is successful in patients with localized cancer. However, prolonged androgen deprivation often leads to hormone refractory condition, associated with disease relapse. ErbB1 and ErbB2 activity has been correlated with androgen-independence. We determined the effects of GW2974, a dual inhibitor of ErbB-1 and ErbB-2 tyrosine kinase activity, on growth, NSE, chromogranin A and osteopontin cytosol content in the androgen-independent prostate cancer cell line PC-3. We found that PC-3 cell growth was inhibited by GW2974, whereas NSE and chromogranin A cell contents were stimulated and osteopontin cytosol level was not affected. The present data may have clinical implications for the treatment of advanced prostate cancer.

Related Articles

Journal Cover

July 2010
Volume 24 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 4.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.4
  • CiteScore Rank: Q1: #68/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.786
  • SCImago Journal Rank (SJR): 0.812
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Terracciano D, Mazzarella C, Di Carlo A, Mariano A, Ferro M, Di Lorenzo G, Giordano A, Altieri V, De Placido S, Macchia V, Macchia V, et al: Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. Oncol Rep 24: 213-217, 2010
APA
Terracciano, D., Mazzarella, C., Di Carlo, A., Mariano, A., Ferro, M., Di Lorenzo, G. ... Macchia, V. (2010). Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. Oncology Reports, 24, 213-217. https://doi.org/10.3892/or_00000848
MLA
Terracciano, D., Mazzarella, C., Di Carlo, A., Mariano, A., Ferro, M., Di Lorenzo, G., Giordano, A., Altieri, V., De Placido, S., Macchia, V."Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content". Oncology Reports 24.1 (2010): 213-217.
Chicago
Terracciano, D., Mazzarella, C., Di Carlo, A., Mariano, A., Ferro, M., Di Lorenzo, G., Giordano, A., Altieri, V., De Placido, S., Macchia, V."Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content". Oncology Reports 24, no. 1 (2010): 213-217. https://doi.org/10.3892/or_00000848